Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary diseaseFDA ...

Ferring Pharmaceuticals today announced a new real-world case series demonstrating that re-induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) resulted in complete responses (CR) in ...

Deep learning models accurately predicted key DCIS biomarkers from pathology slides, supporting active surveillance ...

(CR) rate at any time; 43% six‑month CR rate Low rate of progression to muscle-invasive or higher disease (3.2%) Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), ...

TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response ...

ImmunityBio, Inc. , a vertically integrated commercial-stage immunotherapy company, today announced that five United States patents have been issued to ImmunityBio covering the combination of its ...

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027Hosting virtual ...

May 11, 2026 expert reaction to study on association between GLP-1 use and breast cancer survival and recurrence . A study published in Nature Medicine looks at an association bet ...

A multicenter retrospective review of 269 nail unit squamous cell carcinoma (NSCC) cases found that human papillomavirus (HPV)-related lesions were more often periungual and in situ, whereas subungual ...

Key Points Interested in Aura Biosciences, Inc.? Here are five stocks we like better. Aura Biosciences says its lead drug bel ...

Operator: Good afternoon, and welcome to Relmada Therapeutics First Quarter Earnings Conference Call. At this time, all ...

Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash deal worth $4.1 billion. The acquisition ...